VIR,Vir Biotechnology, Inc. | Healthcare

Healthcare

VIR

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Vir Biotechnology, Inc.VIR

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.

It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.

It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus.

The company was incorporated in 2016 and is headquartered in San Francisco, California.

Latest News >

Arcosa Prices $600 Million Notes Due 2032

Aug 12, 2024

05:08 PM EDT, 08/12/2024 (MT Newswires) -- Arcosa ( ACA ) said Monday it priced its $600 million private offering of 6.875% senior notes due 2032. The offering is slated to close on Aug. 26, the company said. Net proceeds from the offering, together with borrowings, will be used to fund the $1.2 billion acquisition of Stavola's construction materials business,...

Sienna Senior Living Raising $125 Million in a Bought-Deal Share Offering

Aug 12, 2024

05:06 PM EDT, 08/12/2024 (MT Newswires) -- Sienna Senior Living ( LWSCF ) after trade Monday said it is raising $125 million in a bought-deal share offering.. Sienna is selling a syndicate of underwriters 8.34-million shares priced at $15.00 each. It also granted the underwriters an over-allotment option of a further 1.25-million shares if demand warrants. If the over-allotment option...

Tandem Diabetes Care to Release New Update as Battery Issues Persist With X2 Insulin Pump

Aug 12, 2024

05:06 PM EDT, 08/12/2024 (MT Newswires) -- Tandem Diabetes Care ( TNDM ) said Monday that some users continue to face rapid battery depletion of its t:slim X2 insulin pump and indicated it will release a newer version of the application to address the remaining issues. The company initially recalled Apple's ( AAPL ) iOS t:connect mobile app in the...

BMO to Redeem $1 Billion Series J Medium-Term Notes First Tranche

Aug 12, 2024

05:07 PM EDT, 08/12/2024 (MT Newswires) -- Bank of Montreal ( BERZ ) Monday said it will redeem all of its $1 billion Series J Medium-Term Notes (Non-Viability Contingent Capital [NVCC]), First Tranche due Sept. 17, 2029. The redemption will occur Sept. 17. The Notes are redeemable at a redemption price equal to 100% of the principal amount thereof, plus...